The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A comprehensive laboratory‐based program for classification of variants of uncertain significance in hereditary cancer genes
Open accessAbstract
Genetic testing has the potential to guide the prevention and treatment of disease in a variety of settings, and recent technical advances have greatly increased our ability to acquire large amounts of genetic data. The interpretation of this data remains challenging, as the clinical significance of genetic variation detected in the laboratory is not always clear. Although regulatory agencies and professional societies provide some guidance regarding the classification, reporting, and long‐term follow‐up of variants, few protocols for the implementation of these guidelines have been described. Because the primary aim of clinical testing is to provide results to inform medical management, a variant classification program that offers timely, accurate, confident and cost‐effective interpretation of variants should be an integral component of the laboratory process. Here we describe the components of our laboratory's current variant classification program (VCP), based on 20 years of experience and over one million samples tested, using the BRCA1/2 genes as a model. Our VCP has lowered the percentage of tests in which one or more BRCA1/2 variants of uncertain significance (VUSs) are detected to 2.1% in the absence of a pathogenic mutation, demonstrating how the coordinated application of resources toward classification and reclassification significantly impacts the clinical utility of testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955 · cited 1×
“However, non-informative results including VUSs often increase anxiety among patients, family members, and providers who cannot take advantage of the risk assessment, prevention, and therapeutic measures that are available to carriers of known deleterious mutations to modify behavior or lifestyle, or to make important…”
BackgroundEaston, D. F., Deffenbaugh, A. M., Pruss, D., Frye, C., Wenstrup, R. J., Allen-Brady, K., Tavtigian, S. V., Monteiro, A. N. A., Iversen, E. S., Couch, F. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/521032 · Cited by 455
Self-citation
Cited by
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
Yamanaka, S. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.014 · Cited by 1,213
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Self-citationPrevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 467
Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K., Timms, K., Garber, J. E., Herold, C., Ellisen, L., et al. (2015) · Cancer · doi:10.1002/cncr.29010 · Cited by 430
Self-citation
Metadata
- Authors
- Eggington, J. M., Bowles, K. R., Moyes, K., Manley, S., Esterling, L., Sizemore, S., Rosenthal, E., Theisen, A., Saam, J., Arnell, C., Pruss, D., Bennett, J., Burbidge, L. A., Roa, B., & Wenstrup, R. J.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 2013-12-20
- Volume
- 86
- Issue
- 3
- Pages
- 229-237
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W1604692664
- Cited by
- 188
- References
- 3
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.